No Detail Found!

Efects of oral steroid sparing immunosuppressive drugs in long term maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy

Author(s)
Ali Sajjad Department of Medicine, Neurology Section, Aga Khan University and Hospital Karachi, Pakistan.
Sajid Hameed Department of Medicine, Neurology Section, Aga Khan University and Hospital Karachi, Pakistan.
Sara Khan Department of Medicine, Neurology Section, Aga Khan University and Hospital Karachi, Pakistan.
Abstract
Background and objectives: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired treatable autoimmune disorder. Due to limited availability and afordability of IV immunoglobulins and therapeutic plasma exchange in Pakistan, oral immunosuppressive drugs (ISDs) are used despite limited role in literature. The study aimed to determine the response to ISDs in CIDP patients by assessing the frequency of remission, reduction of disability using a neuropathy related disability score called Inflammatory Neuropathy Cause and Treatment score (or INCAT score), as well as reduction in steroid maintenance dose. Methods: The retrospective observational study of six months duration (May to October, 2020) was carried out in Aga Khan University Hospital, Karachi, Pakistan. Medical record of all the patients with idiopathic CIDP taking oral ISDs in last five years was selected which included bio-data, clinical signs and symptoms, medication details, and INCAT scores. Descriptive statistics were described i.e. frequency, percentages, mean/standard deviation using Microsoft Excel v.2021. Results: Out of thirteen patients, Azathioprine was used in nine, Mycophenolate mofetil in two and Cyclosporine in two, with remission (INCAT score improvement = 1) achieved in eight, one and zero patients respectively. Duration of ISDs ranged from three to twenty-four months (average 15.8 months). Patients with monoclonal paraproteinemia and prior exposure to ISDs had a poor response to the introduction of subsequent ISDs. Conclusion: The study describes preliminary experience of the potential role of relatively cheaper and more convenient oral ISDs (especially Azathioprine) as an alternative or sparing agent to first line agents for CIDP and sets the stage for larger scale studies and randomized controlled trials.
Publication Details
Page(s) 1669-1674
Published Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 8, Year: 2024

Request the full text from PASTIC

Keywords
plasmapheresis, IVIG, Chronic inflammatory demyelinating polyradiculoneuropathy, CIDP, Immunosuppressive drugs (ISD)
References
Broers MC,Bunschoten C,Nieboer D,Lingsma HF,Jacobs BC .2019 .Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology, 10(3-4) : 161-172.
Iijima M,Koike H,Hattori N,Tamakoshi A,Katsuno M,Tanaka F .2007 .Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry, 10(9) : 1040-1043.
Oaklander AL,Lunn MP,Hughes RA,Van Schaik IN,Frost C,Chalk CH .2017 .1(1):CD010369. Cochrane Database Syst Rev, 10 : .
Dyck PJ,O'Brien P,Swanson C,Low P,Daube J .1985 .Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology, 10(8) : 1173-1176.
.2009 .Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicenter study. Lancet Neurol, 4422(08) : 70299-0.
Khalid E,Khan H,Nasir A,Abdullah M. .2020 .Referral patterns and diagnoses at a single Neurophysiology Center in Quetta, Pakistan: An audit of 1600 Cases. , 15(3) : 17-21.
Jan Z,Hassan MH,Salman F,Shahzad W,Zarminahil R,Badshah M. .2019 .An analysis of pattern and burden of patients Referred for nerve conduction study in a Tertiary care hospital in Pakistan. Pak J Neurol Sci, 14(3) : 31-36.
Gaebel K,Blackhouse G,Campbell K,Robertson D,Xie F,Assasi N .2010 .Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Open Med, 4(3) : e154.
Breiner A,Barnett C,Bril V .2014 .INCAT disability score: a critical analysis of its measurement properties. Muscle Nerve, 10(2) : 164-169.
Van Schaik IN,Eftimov F,Van Doorn PA,Brusse E,Van den Berg LH,Van der Pol WL .2010 .Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double blind, randomised, controlled trial. Lancet Neurol, 4422(10) : 70021-1.
Cornblath DR .1991 .Report from an Ad Hoc Subcommittiee of the American academy of Neurology AIDS Task Force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyneuropathy. Neurology, 42 : 617-618.
Guptill JT,Runken MC,Eaddy M,Lunacsek O,Fuldeore RM .2019 .Treatment patterns and costs of chronic inflammatory demyelinating polyneuropathy: a claims database analysis. Am Health Drug Benefits, 12(3) : 127-135.
.2014 .. British National Formulary. 8th Edition, : .
Ryan MM,Grattan-Smith PJ,Procopis PG,Morgan G,Ouvrier RA .2000 .Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and longterm outcome. Neuromuscul Disord, 8966(00) : 00119-x.
Dalakas MC,Engel WK .1981 .Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol, 10 : 134-145.
Monaco S,Turri E,Zanusso G,Maistrello B .2004 .Treatment of inflammatory and paraproteinemic neuropathies. Curr Drug Targets Immune Endocr Metabol Disord, 10(2) : 141-148.
Cocito D,Grimaldi S,Paolasso I,Falcone Y,Antonini G,Benedetti L .2011 .Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol, 03495(12) : 1331-1421.
Odaka M,Tatsumoto M,Susuki K,Hirata K Yuki N. K .2003 .Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. J Neurol Neurosurg Psychiatry, 10(8) : 1115-1120.
Hodgkinson SJ,Pollard JD,McLeod JG .1990 .Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry, 10(4) : 327-330.
Barnett MH,Pollard JD,Davies L,McLeod JG .1998 .:aid-mus3>3.0. Muscle Nerve, 10(199804) : 2-8.
Rison RA,Beydoun SR .2016 .Paraproteinemic neuropathy: a practical review. BMC Neurol, 10 : 13.
Viala K,Béhin A,Maisonobe T,Leger JM,Stojkovic T,Davi F .2007 .Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis?. J Neurol Neurosurg Psychiatry, 10(7) : 778-782.
0

Citations

0

Downloads

76

Views